Antibody and antigen binding fragments thereof
US-2024385186-A1 · Nov 21, 2024 · US
Generating metal ion binding proteins
US9518131B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9518131-B2 |
| Application number | US-201414242725-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 1, 2014 |
| Priority date | Apr 2, 2013 |
| Publication date | Dec 13, 2016 |
| Grant date | Dec 13, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides for a method for generating a metal ion binding protein, the method comprising a) integrating the amino acid sequence DDD into CDR1 of a light chain variable region of an antibody or fragment thereof; and b) combining the sequence of step a) with a heavy chain variable region of an antibody or fragment thereof; and c) isolating the protein. Also provided is the use of metal ion binding proteins generated by the method of the present invention for isolation and purification of proteins and for the reversible labeling of a target molecule. Also provided is a metal ion binding anti-CD8 protein.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the targeted generation of antibodies or fragments thereof that bind antigen in a Ca2+ or Mg2+ dependent manner, the method comprising: a) combining SEQ ID No: 1 or a fragment comprising the CDRs of SEQ ID NO: 1 with antibody heavy chain variable regions; b) screening for antibodies that bind antigen in a Ca2+ or Mg2+ dependent manner; and c) identifying individual antibodies or antigen binding fragments thereof that bind antigen in a Ca2+ or Mg2+ dependent manner. 2. The method of claim 1 , wherein said step b) is performed by a method selected from the group consisting of high-throughput ELISA screening, high-throughput cell-based screening, phage display selection, and yeast display selection. 3. The method of claim 1 , wherein said step c) is performed by ELISA or flow cytometry.
Assignees
Inventors
Classifications
against CD8 · CPC title
- C07K16/44Primary
against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Complete light chain, i.e. VL + CL · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9518131B2 cover?
- The present invention provides for a method for generating a metal ion binding protein, the method comprising a) integrating the amino acid sequence DDD into CDR1 of a light chain variable region of an antibody or fragment thereof; and b) combining the sequence of step a) with a heavy chain variable region of an antibody or fragment thereof; and c) isolating the protein. Also provided is the us…
- Who is the assignee on this patent?
- Miltenyi Biotec Gmbh, Miltenyi Biotech Gmbh
- What technology area does this patent fall under?
- Primary CPC classification C07K16/44. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).